Overview

Continuing Treatment With Pegasys and Copegus

Status:
Unknown status
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
Primary objective is to measure sustained viral response given to continuation or prolongation of combined Pegasys&Copegus treatment Secondary objective is to measure histological response given to continuation or prolongation of combined Pegasys&Copegus treatment measured by non-invasive methods
Phase:
Phase 3
Details
Lead Sponsor:
Májbetegekért Alapítvány
Collaborator:
Hoffmann-La Roche
Treatments:
Peginterferon alfa-2a
Ribavirin